NP-118809;1-[4-(DiphenylMethyl)-1-piperazinyl]-3,3-diphenyl-1-propanone

Min.Order / FOB Price:Get Latest Price

0 Metric Ton	Negotiable

0 Metric Ton

Negotiable

Min.Order :0 Metric Ton
Purity: 99%
Payment Terms : T/T

Keywords

41332-24-5 price NP-118809;1-[4-(DiphenylMethyl)-1-piperazinyl]-3,3-diphenyl-1-propanone 41332-24-5 supplier

Quick Details

Appearance:Off-whiwte powder
Application:chemical intermediate,research and development
PackAge:Upone youe needs
ProductionCapacity:|Kiloliter|Month
Storage:-20°C
Transportation:by air or sea

Superiority:

Strong ability in R&D, Production capacity:gram to kg to Ton with lowest cost.we own independent R&D in changzhou city. All our manufacture bases and facilities are GMP approved. Supported by our highly qualified team of professionals and technicians.Better offer,Higher quality,Good service.

Details:

IC50 Value: 0.11uM (for N-type Calcium channel) [1]
NP-118809 is a potent N-type calcium channel blockers which have good selectivity over L-type calcium channels.
in vitro: NP-118809, exhibited increased N-type channel blockade (IC50=0.11 uM) and was 111-fold more selective for N-type channels (L-type calcium channel IC50=12.2 uM) [1]. In the N,4-dibenzhydryl-piperazine-1-carboxamide series (21-27), non-substituted derivative (21) showed a similar inhibitory activity for N-type calcium channels (est. IC50=0.15 uM) as that of parent compound, NP-118809 (est. IC50=0.11 uM). 1-[Phenyl(pyridin-4-yl)methyl]piperazine (42), with no substituent on the nitrogen showed good N-type blocking activity (est. IC50=0.06 uM) while the N-methylated analog (43) was an order of magnitude less potent (est. IC50=0.69 uM) [2].
in vivo: NP-118809, i.v. at 2 mg/kg or p.o. at 10 mg/kg in rats, showed acceptable absorption (Tmax=2.3 hr) and half-life (2.1 hr) characteristics and a mean oral bioavailability of 30%. Both compounds were widely distributed outside of plasma and/or bound to plasma proteins. Upon i.p. administration of NP-118809 and NP-078585 at 25 mg/kg, both showed analgesic activity in Phase IIA portions of the rat formalin model. A single 1 uM dose application of NP-078585 blocked hERG currents showing its potential for cardiovascular liability [1].

View All